Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherDepreciationAndAmortization.
The source filing: Agios Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:56 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001439222-26-000118
| (In thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Operating activities | ||
| Net loss | $(199,814) | $(201,309) |
| Adjustments to reconcile net loss from operations to net cash used in operating activities: | ||
| Depreciation and amortization | 2,713 | 2,537 |
| Stock-based compensation expense | 31,482 | 26,051 |
| Net accretion of discount on marketable securities | (2,271) | (3,768) |
| Loss on disposal of property and equipment | — | 5 |
| Non-cash operating lease expense | 6,579 | 6,094 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Agios Pharmaceuticals's D&A?
- Agios Pharmaceuticals (AGIO) reported D&A of $1.35M in Q2 2026.
- How has Agios Pharmaceuticals's D&A changed year-over-year?
- Agios Pharmaceuticals's D&A increased by 7.2% year-over-year, from $1.26M to $1.35M.
- What is the long-term trend for Agios Pharmaceuticals's D&A?
- Over 4 years (2021 to 2025), Agios Pharmaceuticals's D&A has grown at a -13.5% compound annual growth rate (CAGR), from $9.24M to $5.18M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Agios Pharmaceuticals's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude